Agoracom Blog Home

Archive for the ‘All Recent Posts’ Category

« Older Entries
Newer Entries »

Applied BioSciences $APPB – Reports Second Quarter Fiscal Year 2020 Financial Results and Outlines Corporate Strategy $CGRW $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca

Posted by AGORACOM at 8:45 AM on Friday, November 15th, 2019
  • Successfully building BioPharma pipeline in high-value indications
  • Company plans to advance IND-cleared program into a Phase 1 study in a metabolic disease indication in early 2020
  • Strategic corporate shift to fully focus on BioPharma Division unlocks opportunities for non-dilutive capital to fund pipeline

Applied BioSciences Corp. (OTCQB:APPB) (“Applied” or the “Company”), today announced its financial results for the second quarter Fiscal Year 2020 ended September 30, 2019. The Company also provided an update on its corporate and clinical progress.

“We continue to push forward on all fronts as we work to establish Applied as a leader in the development and commercialization of novel, science-driven, synthetic endocannabinoid therapeutics / biopharmaceuticals and impact areas of significant unmet need,” commented Dr. Raymond Urbanski, Chief Executive Officer of Applied. “Over the course of the past quarter, we have made notable strides on the corporate and clinical front and remain diligent in working to drive value for all stakeholders.”

“We continued to build out our BioPharma division and have established a Scientific Advisory Board of leading experts in the endocannabinoid space. We were pleased to have welcomed our inaugural members Judith Korner, M.D. and Patricia Reggio, Ph.D., who will play an integral role as we look to optimize our therapeutic pipeline and look to make additional appointments in the near term to help drive this business unit forward. Additionally, we have continued to execute on our robust business development initiatives and remain in late-stage discussions to in-license our product candidates that we believe have the potential to address a number of areas with significant unmet need. In tandem, we continue to remain opportunistic in accessing the necessary non-dilutive funding and capital through strategic investments from which we believe will provide us with the foundation and momentum to move forward.”

Applied BioPharma: developing science-driven synthetic cannabinoid therapeutics that satisfy unmet medical needs and continue to drive innovation in the endocannabinoid space.

The Applied BioPharma division is focused on the development and commercialization of novel therapeutics that target the endocannabinoid system (ECS).

Applied Biopharma has to date developed partnerships with leading academic and research institutions and has exclusively licensed patented, synthetically derived small molecule candidates which target the ECS G-protein coupled receptors (GPCRs) e.g., the cannabinoid receptor 1 and cannabinoid receptor 2, for the treatment of metabolic diseases (type 2 diabetes, obesity, fatty liver disease) and inflammation (pulmonary inflammation, optic nerve inflammation following traumatic brain injury and ischemic/reperfusion injury such as acute kidney injury post-transplant and acute myocardial infarction (heart attack).

The Company’s growing pipeline is comprised of selective CB1 and CB2 agonist, inverse agonist and antagonists utilizing multiple scaffolds and state-of-the-art medicinal chemistry across several academic centers and institutions.

  • Applied expects to advance the first of its preclinical programs into open INDs in 2020.
    • ABP-1902, its lead CB2 agonist, intended for mitigating the deleterious effects of ischemic-reperfusion injury.
    • ABP-1901, its lead CB2 inverse agonist, which has demonstrated effectiveness in limiting or reversing damage due to neuroinflammation.
  • Applied expects to advance the first of its clinical programs into a Phase 1 study in early to mid-2020.

The Company is actively advancing and seeking additional in-license opportunities with the goal of developing an industry-leading pipeline of endocannabinoid system-targeted drug candidates that address significant unmet needs across a wide range of therapeutic areas.

Applied Products: portfolio of consumer, animal health, women’s health and sports medicine of hemp-derived, THC-free, pharmaceutical grade CBD isolates and distribution products, all of which ship to the majority of U.S., as well as to multiple non-U.S. countries.

The Applied Products business unit is focused on maximizing top-line revenue through selective investments in product lines and marketing campaigns (increase share-of-voice), continually reevaluating the endocannabinoid Health & Wellness environment for opportunities and developing and implementing a nutraceutical strategy.

Applied Products has seen a modest year-over-year increase in top line revenue. At this time the Board, with the understanding that to be successful in the lucrative yet dynamic and very competitive consumer CBD space would require significant resource and capital allocations, is evaluating various strategic options for this business unit.

Trace Analytics, Inc: Applied’s majority owned subsidiary scalable analytics cannabis/cannabinoid laboratory poised to meet the demands for mandated regulatory cannabis/cannabinoid testing.

In July 2019, Trace Analytics was contracted for services with the Washington State Department of Agriculture (WSDA). This contract includes testing Industrial Hemp samples and include percentage testing for post-decarboxylation delta 9-tetrahydrocannabidiol (THC) and delta 9-tetrahydocannabinolic acid (THC-A) to ensure the percentages of certain cannabinoids are below Federal limits.

Applied is currently in late-stage discussions for a strategic transaction, expected to close by year end.

Upcoming Milestones Expected to Drive Value

  • Finalize the in-licensing of product candidates to build pipeline for the Applied BioPharma division.
  • Closing on the sale of Trace Analytics leading to the infusion of non-dilutive capital into the company.
  • Finalize and execute on the strategic options for Applied Products.
  • Successfully execute overall strategy of the Company and business development efforts.
  • Engage with key stakeholders in the investment community and execute on the robust effort to raise awareness of the Company.
  • Uplist to a National Exchange.

Summary of Financial Results for Second Quarter FY2020 Ended September 30, 2019

For the quarter ended September 30, 2019, the Company reported net loss of approximately $777,746 or net loss per diluted share of $0.06, compared to a net loss of approximately $110,423 or a net loss per diluted share of $0.01, for the quarter ended September 30, 2018.

The Company reported revenues from Applied BioSciences’ CBD product lines was $169,654 and $59,400 during the six months ended September 30, 2019 and 2018, respectively. The increase reflects higher sales across all of the Company’s CBD brand product lines, most notably in its topical products, combined with expansion into sales of bulk hemp seed and raw CBD. Service revenue resulting from the Company’s lab testing is attributed solely to the acquisition of Trace Analytics in January 2019, and totaled $286,077 for the six months ended September 30, 2019.

General and administrative expenses increased $519,140 to $707,192 for the three months ended September 30, 2019 as compared to $188,052 for the three months ended September 30, 2018. The increase was mainly attributable to the acquisition of Trace Analytics and addition of our Applied BioPharma subsidiary, with general and administrative expenses for the remainder of the Company.

The Company ended the quarter with $73,412 in cash and cash equivalents. The Company is actively evaluating opportunities to fund continued growth in its products and services revenue along with planned business development activities for Applied BioPharma and anticipates closing a financing by the end of first quarter Fiscal Year 2020.

About Applied BioSciences Corp.

Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas. We also deliver high-quality consumer and OTC THC-free CBD products that promote overall health and wellbeing as well as state-of-the-art testing and analytics capabilities to our customers. For more information, visit appliedbiocorp.com and connect with the Company on Twitter, Facebook and LinkedIn.

Tags: , , , , , , , , , , ,
Posted in All Recent Posts, Applied BioSciences | Comments Off on Applied BioSciences $APPB – Reports Second Quarter Fiscal Year 2020 Financial Results and Outlines Corporate Strategy $CGRW $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca

Applied BioSciences $APPB – New, Online Resource Designed to Assist Pharmacists With CBD Products $CGRW $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca

Posted by AGORACOM at 2:30 PM on Thursday, November 14th, 2019

SPONSOR: Applied Biosciences Corp. is a vertically integrated company focused on the development of science-driven cannabinoid therapeutics and biopharmaceuticals, as well as state-of-the-art testing and analytics. As a leading company in the CBD, Pet and Health and Wellness space, the company is currently shipping to the majority of US states as well as to 5 International countries. Click Here for More Info

The National Community Pharmacists Association (NCPA) has launched a new resource for pharmacists looking to understand and purchase reliable cannabidiol (CBD) products, called the NCPA CBD Source.

The online resource features CBD products that have been tested for concentrations of all cannabinoids, including CBD and tetrahydrocannabinol (THC), by an independent, third-party lab. The site also features experts that pharmacists can contact with questions regarding buying, selling, and marketing. In addition, pharmacists will be able to evaluate each company included in the resource, as well as see each company’s products.

CBD products have exploded in recent months following the Hemp Farming Act of 2018, which removed hemp from the list of Schedule I controlled substances. According to a statement from NCPA, the United States CBD industry grew by nearly 40% in 2017, and is expected to reach $22 billion by 2024.

CBD can help relieve pain and inflammation resulting from chronic illnesses, as well as boost the immune system, and these effects have led to a flood of patient interest.

“Many pharmacies are deciding to sell CBD products because of the patient demand and because, as the medication expert, they can serve as the source of truth,” said NCPA CEO B. Douglas Hoey, RPh, MBA.

Carter High, PharmD, of Best Value Rhome Pharmacy, said he plans on using the service to bolster the knowledge and products that he already trusts. CBD products are new to the pharmacy wheelhouse, High said, and he gets many phone calls with sales pitches from various CBD companies.

“It gets a little confusing as to whether or not they’re just talking a really good sales pitch, or if they really do have a genuine product,” High said.

High said it’s important for pharmacists to make sure they understand the uses and mechanisms of CBD products, but that this can be challenging given the crowded marketplace.

“Understanding just how CBD affects the body is a very good avenue for a pharmacist to delineate themselves as a knowledge expert on a new upcoming way of how to help patients out,” High said. “A marketplace such as [NCPA CBD Source] fills a very big gap that was missing, and helps from an efficiency standpoint at the store level.”

While he is excited to use the resources provided, High did emphasize that it doesn’t relieve pharmacists of the responsibility to ensure that the products are reliable, safe, and right for each patient. It does, however, help reassure pharmacists that the decisions they are making are the right ones, he added.

REFERENCE

NCPA, PRS Launch First-of-its-Kind “CBD Source” Tool for Pharmacists

https://www.ncpanet.org/newsroom/news-releases/2019/10/29/ncpa-prs-launch-first-of-its-kind-cbd-source-tool-for-pharmacists.

Tags: , , , , , , , , , , ,
Posted in All Recent Posts, Applied BioSciences | Comments Off on Applied BioSciences $APPB – New, Online Resource Designed to Assist Pharmacists With CBD Products $CGRW $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca

New Age Metals $NAM.ca – Sales Revenue of #Palladium to Soar in the Near Future Owing to Growing Consumer Adoption $WG.ca $XTM.ca $WM.ca $PDL.ca

Posted by AGORACOM-JC at 12:59 PM on Thursday, November 14th, 2019

SPONSOR: New Age Metals Inc. The company’s Lithium Division has already made significant acquisitions in Canada and the USA. The company also owns one of North America’s largest primary platinum group metals deposit in Sudbury, Canada. Updated NI 43-101 Mineral Resource Estimate 2,867,000 PdEq Measured and Indicated Ounces, with an additional 1,059,000 PdEq Ounces in the Inferred. Learn More.

Sales Revenue of Palladium to Soar in the Near Future Owing to Growing Consumer Adoption

  • Global market for palladium is likely to experience significant growth with declining demand for metals and increasing demand for recycling metals, leading to palladium demand outstripping the supply.
  • In addition, changing prospects of investments in palladium have also contributed to the growth of the market

By: PMR Research

Palladium is a lustrous silvery-white rare metal used in a diverse range of applications. The metal with other elements such as osmium, iridium, ruthenium, rhodium, and platinum are referred to as Platinum Group Metals (PGM). Palladium is majorly consumed in the automotive industry as catalytic converters, manufacturing of electronics and jewelry, as well as chemical and dental applications. Palladium is sourced from two major sources, viz., mine production and recycling.

The global market for palladium is likely to experience significant growth with declining demand for metals and increasing demand for recycling metals, leading to palladium demand outstripping the supply. In addition, changing prospects of investments in palladium have also contributed to the growth of the market. Several new palladium exchange-traded funds by companies such as Absa Capital in South Africa are expected to create a significant boost for the palladium market.

Growing demand for palladium in catalytic converters in the automotive industry in vehicles exhausts are one of the major growth factors driving the palladium market. Demand for the metal from other sectors such as jewelry and industrial are also anticipated to contribute to the growth of the market. However, rising prices of palladium owing to supply issues in South Africa and declining state stockpiles in Russia are expected to hamper the growth of the market. North America was the largest consumer for palladium, followed by China owing to the presence of the vast automotive industry in the region. Future market growth is expected to be from Asia Pacific with the growing industrial activities in emerging economies such as India. These factors are expected to provide new opportunities for the growth of the market.

Source: https://www.zebvo.com/2019/11/14/sales-revenue-of-palladium-to-soar-in-the-near-future-owing-to-growing-consumer-adoption/

Tags: , , , , , , ,
Posted in All Recent Posts, New Age Metals | Comments Off on New Age Metals $NAM.ca – Sales Revenue of #Palladium to Soar in the Near Future Owing to Growing Consumer Adoption $WG.ca $XTM.ca $WM.ca $PDL.ca

American Creek $AMK.ca Treaty Creek Moves Closer to Eric Sprott’s Prediction of 10 to 20 Million Ounce $TUD.ca $SII.ca $GTT.ca $AFF.ca $SEA.ca $SA $PVG.ca

Posted by AGORACOM at 11:47 AM on Thursday, November 14th, 2019
  • 23 holes drilled in the last two years have intersected significant mineralization and dramatically increased the size of the Goldstorm deposit at Treaty Creek
  • Eric Sprott re-emphasized the potential of the project in a podcast where he stated that he is “hoping they can prove up a 20-million-ounce deposit”
https://www.sprottmoney.com/Blog/after-three-weeks-going-sideways-gold-and-silver-just-woke-up-weekly-wrap-up-october-25-2019.html

11:30 –“I still believe there’s going to be huge deposit proven up there. If we get the right environment in precious metals, which it looks like we might be getting here, people are going to start looking at these things again, and it could be very, very exciting, so…and I am, kind of, hoping that they can ultimately pull up, like, a 20 million ounce deposit there. So these stocks would prove to be very, very inexpensive”

SUMMARIZING THE 2019 PROGRAM

The Company’s JV partner, Tudor Gold’s 2019 exploration program at the Goldstorm Zone on Treaty Creek totalled 9,781.8 meters with 14 diamond drill holes. This year’s drilling program generated the best near-surface results attained to date on the project. Specifically, in addition to several hundred meters extension along strike to the northeast, the 2019 program significantly expanded the mineralized limits to the southeast, where one of the best near-surface intervals averaged 2 g/t Au over 87m, within 336 m averaging 1 g/t Au in hole GS19-52.

RESULTS OF THE FINAL 5 DRILL HOLES

  • Hole GS19-49 was drilled to 960.1 m, at -80° dip, on Section 111+00 NE next to the previously announced vertical hole GS19-48, which yielded 0.725 g/t Au over 838.5m, including an upper horizon that averaged 1.048 g/t gold Au over 328.5 m. Hole GS19-49 returned equally impressive results with a comparable 0.7 g/t Au over 826.5 m and the upper horizon averaging 1 g/t Au over 249 m 
  • Along the same section, hole GS19-52 (-50° dip at 115° azimuth) was drilled much longer than expected because the Goldstorm System continues at least 700 m to the southeast ; GS19-52 averaged 1 g/t gold over 336 meters with a higher grade core of 2 g/t gold over 87 meters within the upper horizon.

Tudor Gold Exploration Manager, Ken Konkin explained: “Clearly the results of the previously reported deep vertical step-out holes demonstrate the impressive size and grade consistency of the Goldstorm system. Within the overall mineralized package of fragmental intermediate volcanic rocks there are several sub-horizontal horizons of significantly higher gold grades. The uppermost portions of the previously reported holes GS19-42, GS19-47 and GS19-48 contained respectively, 1.268 g/t gold over 252 m, 0.828 g/t gold over 301.5 m and 1.048 g/t gold over 328.5 m. We now have several other drill holes with excellent near-surface gold values to add to this list of growing intercepts. GS19-52 has returned the highest core gold grades of 2.006 g/t Au over 87 m within a 336m intercept of 1.004 g/t Au.

These intercepts are part of the uppermost portion of the Goldstorm system which we refer to as the ‘300 Horizon’. The ‘300 Horizon’ remains open along strike to the northeast as well as to the southeast. In addition, the lower horizons of the Goldstorm system also remain open in all directions and the lowest horizon is open at depth.”

Furthermore, Mr. Konkin added: “We are seeing consistent silver and copper mineralization associated with the deeper gold horizons such as the previously reported 151.5 m zone of 0.572 g/t gold, 8.5 g/t silver and 0.21% copper that was intercepted from 665.0 to 816.5 m in GS19-47 and a 66.0 m zone with 0.958 g/t gold, 3.9 g/t silver and 0.35% copper, whichwas intercepted from 874.5 to 940.5 m in GS19-48. Similarly, we have now seen in GS19-49, a 78 m intercept averaging 1.145 g/t gold, 11.2 g/t silver and 0.21% copper (750-828 m) and in GS19-52 an 88.5 m interval averaging 0.352 g/t gold, 9.3 g/t silver and 0.25% copper (515-603.5 m). Not only does the Goldstorm Zone remain open at depth and along strike, we are now seeing base-metal associations possibly as part of a zonation within the hydrothermal system.”

The final three footwall extension holes (GS19-50, GS19-51 and GS19-53) were completed on section 110+00 NE. These were successful in extending the width of the mineralized zone to the southeast:

  • Hole GS19-50 returned an average of 0.602 g/t Au over 577.5 m including 0.811 g/t Au over 267.0 m in the ‘300 Horizon‘
  • Hole GS19-51 returned an average of 0.721 g/t Au over 246 m in the ‘300 Horizon’ and a lower horizon that averages 1.017 g/t Au over 40.5 m.
  • Hole GS19-53 returned an average of 0.984 g/t Au over 147.0 m in the ‘300 Horizon’
Cannot view this image? Visit: https://orders.newsfilecorp.com/files/682/49176_99c64899f4a48b79_001.jpg

About American Creek

American Creek is a Canadian junior mineral exploration company with a strong portfolio of gold and silver properties in British Columbia.

Three of those properties are located in the prolific “Golden Triangle”; the Treaty Creek and Electrum joint venture projects with Tudor Gold/Walter Storm as well as the 100% owned past producing Dunwell Mine.

The Treaty Creek Project is a Joint Venture with Tudor Gold owning 60% and acting as operator. American Creek and Teuton Resources each have 20% interests in the project. American Creek and Teuton are both fully carried until such time as a Production Notice is issued, at which time they are required to contribute their respective 20% share of development costs. Until such time, Tudor is required to fund all exploration and development costs while both American Creek and Teuton have “free rides”.

More information about the Treaty Creek Project can be found here: https://americancreek.com/index.php/projects/treaty-creek/home

A drill program is also ongoing on American Creek’s 100% owned Dunwell Mine property located near Stewart. More information can be found here: https://americancreek.com/index.php/projects/dunwell-mine

The Corporation also holds the Gold Hill, Austruck-Bonanza, Ample Goldmax, Silver Side, and Glitter King properties located in other prospective areas of the province.

For further information please contact Kelvin Burton at: Phone: 403 752-4040 or Email: [email protected]. Information relating to the Corporation is available on its website at www.americancreek.com.

Hub on Agoracom
  FULL DISCLOSURE: American Creek is an advertising client of AGORA Internet Relations Corp.

Tags: , , , , , , , , , , , , , , , ,
Posted in All Recent Posts, American Creek Resources Ltd. | Comments Off on American Creek $AMK.ca Treaty Creek Moves Closer to Eric Sprott’s Prediction of 10 to 20 Million Ounce $TUD.ca $SII.ca $GTT.ca $AFF.ca $SEA.ca $SA $PVG.ca

ZEN Graphene Solutions $ZEN.ca – Reports on Multiple Intellectual Property Licensing Agreements $LLG.ca $FMS.ca $NGC.ca $CVE.ca $DNI.ca

Posted by AGORACOM at 8:26 AM on Thursday, November 14th, 2019

Thunder Bay, Ontario–(Newsfile Corp. – November 14, 2019) – ZEN Graphene Solutions Ltd. (TSXV:ZEN) (“ZEN” or the “Company“)  has signed the definitive graphene manufacturing process License Agreement referred to in a news release on May 30, 2019. This agreement licenses to ZEN the intellectual property created by scientists and laboratories within a renowned Canadian University. This agreement has no expiry date and provides that a royalty is payable by ZEN based on the annual amount of material processed under the intellectual property.

The company also reports that it has signed an 18-month exclusive initial option agreement with the University of Guelph (Guelph) for intellectual property regarding an electrochemical exfoliation (ECE) process to produce Graphene Oxide. In addition, the University of British Columbia (UBC) and ZEN have begun negotiating a Collaborative Research Agreement (CRA) template that will form the basis of each agreement with various UBC researchers. Neither Guelph nor UBC is party to the definitive agreement mentioned above.

Francis Dubé, CEO commented: “These three Canadian universities are contributing significantly to unlocking the value of the Albany Graphite deposit and creating a strong intellectual property foundation for the company. We are happy to bring investment dollars, both directly and indirectly, via various grants to these academic partners and will continue to support research opportunities in the exciting field of nanoscience.”

The definitive License Agreement took effect November 1, 2019 and subsequently ZEN has begun investing in certain equipment required under this process. ZEN anticipates that the equipment will be installed during Q1 2020 at its Guelph location thereby allowing the Company to start production of this graphene product for market development and subsequent sale.

The exclusive agreement with Guelph results from research and development by Prof. Aicheng Chen and his group. Early results from this process are very encouraging with Albany Graphite significantly outperforming both flake/sedimentary graphite and synthetic graphite, demonstrating again the uniqueness of ZEN’s graphite and its superior performance to exfoliate into graphene products.

Several researchers at UBC Okanagan continue to work with ZEN’s material in multiple areas including the synthesis of Graphene Quantum Dots and Graphene Oxide, along with multiple applications including battery anodes, polymers, aluminum, concrete, coatings, and others. Given that collaboration amongst UBC researchers is expected, this intellectual property template should accelerate the science by eliminating repetitive negotiation with each research team at UBC. ZEN will report on material final agreements with UBC as they are executed.

About ZEN Graphene Solutions Ltd.

ZEN is an emerging graphene technology solutions company with a focus on the development of graphene-based nanomaterial products and applications. The unique Albany Graphite Project provides the company with a competitive advantage in the potential graphene market as independent labs in Japan, UK, Israel, USA and Canada have independently demonstrated that ZEN’s Albany Graphite/Naturally PureTM is an ideal precursor material which easily converts (exfoliates) to graphene, using a variety of mechanical, chemical and electrochemical methods.

For further information:

Dr. Francis Dubé, Chief Executive Officer
Tel: +1 (289) 821-2820
Email: [email protected]

Tags: , , , , , , , , ,
Posted in All Recent Posts, Zen Graphene Solutions | Comments Off on ZEN Graphene Solutions $ZEN.ca – Reports on Multiple Intellectual Property Licensing Agreements $LLG.ca $FMS.ca $NGC.ca $CVE.ca $DNI.ca

Empower Clinics $CBDT.ca Reports Q3 2019 Results Highlighted by a 137% increase in clinic revenues compared to Q3 2018 $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:23 AM on Thursday, November 14th, 2019
  • 5,807 patient visits generated revenue of $663,003, compared to 1,864 patient visits that generated $279,850 for Q3 2018.
  • Cash used in operating activities improved by $1,309,913 from $3,129,583 for YTD 2018, compared to $1,819,670 for YTD 2019.

VANCOUVER, Nov. 14, 2019  - EMPOWER CLINICS INC. (CSE: CBDT) (Frankfurt 8EC) (OTC: EPWCF) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company, and a multi-state operator of medical health & wellness clinics in the U.S., has filed today its unaudited condensed interim consolidated financial statements for the three and nine months ended September 30th, 2019 and related management’s discussion and analysis, both of which are available at www.SEDAR.com. All financial information in this press release is reported in United States dollars, unless otherwise indicated.

“Our focus on operational excellence and cost controls are key contributors to strong year-over-year growth numbers and the reduction in direct clinic expense, as we continue to serve the 165,000 patients in our database,” said Steven McAuley, Empowers Chairman & CEO. “The Company is beginning to fulfill its promise of vertical integration with the build-out of the extraction and production center in Portland, OR plus with an increased focus on our proprietary CBD product lines and diversified clinic revenues, the Company has a clear path of growth and profitability going forward.”

Q3 2019 Highlights

  • 5,807 patient visits generated revenue of $663,003, compared to 1,864 patient visits that generated $279,850 for Q3 2018.

  • Net loss of $504,531, compared to $378,657 for Q3 2018, which was primarily driven by increased revenues and fair value adjustments offset by net increased in operating expenses related to the operations of Sun Valley.

  • Cash used in operating activities improved by $1,309,913 from $3,129,583 for YTD 2018, compared to $1,819,670 for YTD 2019.

  • Cash at September 30, 2019 of $178,578, compared to $157,668 at December 31, 2018, which was primarily driven by debt and equity financings during the nine months ended September 30, 2019 and partially offset by cash used in operations, the cash investment in Sun Valley and cash investment in Sun Valley Health Franchise launch.

Highlights

  • Strategic redirection: The Company has been re-positioning its overall strategy to become a vertically integrated health and wellness brand that connects to its 165,000 patients using a data driven focus to improve patients’ lives with products, technology and health systems.

  • Experienced and Seasoned Board of Directors: The Company Board of Directors includes its CEO Steven McAuley, Dustin Klein, the Co-Founder of Sun Valley Clinics and the SVP, Business Development and Andrejs Bunkse, owner and practicing attorney of Rain Legal and Counsel to numerous cannabis enterprises in the U.S. and Canada.

  • Strategic Development: The Company has opened its first hemp-derived CBD extraction facility in greater Portland, Oregon with the first extraction system expected to have the capacity to produce 6,000 kg of extracted product per year. The Company took possession of the new extraction facility June 1st, 2019 and has been awarded it’s hemp-handlers licence from the Oregon Department of Agriculture, allowing the Company to enter the next phase of build-out and full operations in 2019. The Company expects preliminary production of its Sollievo CBD line to take place in the extraction center in 4Q 2019.

  • Strategic Partnership: The Company has entered into a Letter of Intent (“LOI”) to form a Joint Venture Partnership (“JV”) with Heritage Cannabis Holdings Corp (CSE: CANN) (“Heritage”). Terms of the LOI have Empower and Heritage each with a 50% ownership of the JV. Heritage will install extraction units and related downstream extraction equipment inside Empower’s existing licenced hemp processing facility in Sandy, Oregon. Once operational, the JV will begin producing proprietary branded products for Empower’s clinics and third party partners for distribution in the United States.

2019 Outlook and Catalysts

  • Enhanced Corporate Governance: The Company has prioritized corporate governance practices under the leadership of its Board of Directors and Chairman Steven McAuley, to ensure financial and accounting controls operate at the highest of standards.

  • Improved Capital Markets Profile: Empower is diversifying its business model to become a vertically integrated operator in the global cannabis sector with a focus on patient care, CBD product distribution, research & development and CBD product extraction. The Company believes this will appeal to a broader base of shareholders and investors and provide greater access to capital and improved trading liquidity.

  • Increased Patient Access: With a rapidly expanding company-owned clinic network and significant expansion opportunity through the Sun Valley Health franchise model, Empower anticipates it will grow its total patient list substantially in the years ahead. This is expected to provide greater opportunity for treatment analysis using artificial intelligence (AI), through progressive initiatives that include adding the Endocanna DNA test kit to the Company product & service offering in clinics and online. Ensuring the Company is a leader in understanding the efficacy of cannabis-related treatment options is an imperative.

  • Focus on CBD Product Sales: The Company has launched its online store to sell its lines of hemp-derived CBD based products and premium health & wellness supplements. Customers can purchase products, including CBD lotions, tinctures, spectrum oils, capsules, lozenges, patches, e-drinks, topical lotions, gel caps, hemp extract drops and pet-elixir hemp extract drops. Patients and customers will be able to access Sun Valley Health customer service, home delivery and e-commerce platforms.

  • Market Leading Technology: Empower utilizes market-leading patient electronic management and POS system that is HIPAA compliant and provides deep insight to patient care. The Company supports remote patients using its tele-medicine portal, enabling patients who do not live near one of its clinic locations, or are disabled or unable to come to a location, to still benefit from a doctor consultation.

  • New Modalities and Services: The Company has launched new physician based modalities and services into the Sun Valley Health clinics and has commenced booking appointments and providing the new services. Each of these services provides the opportunity for increased patient retention, higher revenue per patient visit and increased patient visits per year. The new services include:

    • Physician’s CBD Enhanced Massage, Acupuncture, or Cupping Sessions

    • CBD-Cannabis-Supplement Consumption & Coaching Consultation

    • Introduction to Alternative Health and Cannabinoid Therapies by a Physician

    • Comprehensive Naturopathic Patient Analysis & Consultation

    • Dietary Antigen Testing, Physician Consultation/Action Plan, & Concierge Blood Draw

    • Neurotransmitter (urine) Profile & Physician Consultation/Action Plan

    • Spectracell Micronutrient Test & Physician Consultation/Action Plan
  • Launches Nationwide Franchise: The Company has launched its nationwide franchise program under the Sun Valley Health brand to dramatically grow our clinic & store footprint increasing direct access to patients and to sell hemp-derived CBD products and premium wellness products directly to our customers and online at our new e-commerce store at www.sunvalleyhealth.com

Financial Summary

  $, except patient visits Three months ended September 30, Nine months ended September 30,
  2019 2018 2019 2018
Patient visits 5,807 1,864 11,304 6,293
Clinic revenues 663,003 279,850 1,406,872 894,477
Direct clinic expenses (55,397) (88,956) (177,560) (301,392)
Loss from operations (843,897) (405,048) (2,547,276) (3,716,474)
Net loss (504,531) (378,657) (2,359,579) (5,132,848)
Net loss per share (0.00) (0.01) (0.02) (0.09)

Financial Performance

Clinic revenues for Q3 2019 were $663,003, compared to Q3 2018 revenues of $279,850. This increase over the prior year is attributable to the acquisition of Sun Valley Clinics.

Direct clinic expenses for Q3 2019 were $55,397, compared to Q3 2018 direct clinic expenses of $88,956. These expenses declined despite the increase in revenues due to improved operational controls to align labor cost with direct patient consultations. The Company employs a diverse mix of physicians and practitioners.

Net loss from operations for Q3 2019 was $843,897, compared to Q3 2018 net loss of $405,048. This increase in loss over prior year is primarily attributable operating expenses increasing due to timing of recognition of the expense associated with non-cash share-based awards to management.

Net loss for Q3 2019 was $504,531, respectively, compared to Q3 2018 net loss of $378,657. This increase over prior year is primarily attributable to the increase in operating expenses as noted above, which was partially offset by gains on change in fair value of the conversion option of convertible debentures and warrants.

During Q3 2019, the Company used $1,819,670 in cash from operations after changes in non-cash working capital. The Company invested $629,636 for the acquisition of Sun Valley Clinics and raised $2,470,216 via proceeds from various issuances of shares, convertible debentures and notes.

Please refer to the Company’s unaudited condensed interim consolidated financial statements, related notes and accompanying management discussion and analysis for a full review of the operations.

ABOUT EMPOWER

Empower is a vertically integrated and growth-oriented CBD life sciences company, and a multi-state operator of medical health & wellness clinics, operating the Sun Valley Health clinic brand www.sunvalleyhealth.com, for its nine corporate locations and for franchises in the United States. As a CBD product manufacturer under the Sollievo brand, the Company distributes its lines through clinics, online and through retail partners. Extraction operations are currently being developed in the Company’s new extraction facility in Oregon.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the terms of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that the hemp-based CBD extraction facility may not be fully operational in 2019 if at all; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE Empower Clinics Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2019/14/c6801.html

Investors: Steve Low, Boom Capital Markets, [email protected], 647-620-5101; Investors: Steven McAuley, CEO, [email protected], 604-789-2146; For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARICopyright CNW Group 2019

Tags: , , , , , , ,
Posted in All Recent Posts, Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca Reports Q3 2019 Results Highlighted by a 137% increase in clinic revenues compared to Q3 2018 $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

CLIENT FEATURE: Empower Clinics With 165,000 Patients Already, $CBDT.ca Is Positioned To Become A Medical #Cannabis & #CBD Retail Killer $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 4:30 PM on Wednesday, November 13th, 2019

Why Empower Clinics?

  • A leading owner/operator of physician staffed health and pain management clinics.
  • Patient database of over 165,000 patients 
  • Platform generating $4MM USD in revenue annually (2019)
  • Q3 2019 preliminary unaudited revenue saw a year over year growth of approximately 138%
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Launching CBD extraction facility
  • First extraction system capacity = 6,000 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025

 The Team

 The Products

  • Commenced selling its proprietary line of CBD-based products called SOLLIEVO
  • Empower’s patient base and customers are expected to benefit from access to high margin derivative products, including CBD lotion, tinctures, spectrum oils, capsules, lozenges, patches, e-drinks, topical lotions, gel caps, hemp extract drops and pet elixir hemp extract drops.
  • Patients and customers will be able to access Empower’s home delivery and e-commerce platform.

CBD Extraction

  • Opening first CBD Extraction facility in Portland, OR.
  • 5,000 sq. ft. leased building with first extraction system capable of producing 20kg per day of 99% spectrum oil, isolate or distillate
  • Current wholesale pricing is $6,500 USD per kg with annual capacity of 6,000kg an estimated $39MM USD revenue.
  • Facility can scale to four extraction systems for up to 24,000kg of product and over $150MM USD revenue

FULL DISCLOSURE: Empower Clinics is an advertising client of AGORA Internet Relations Corp.

Tags: , , , , , , ,
Posted in All Recent Posts, Empower Clinics Inc. | Comments Off on CLIENT FEATURE: Empower Clinics With 165,000 Patients Already, $CBDT.ca Is Positioned To Become A Medical #Cannabis & #CBD Retail Killer $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

CardioComm Solutions $EKG.ca – Digital Health #Mhealth Market Value to Reach USD 511 Billion by 2026 $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 3:21 PM on Wednesday, November 13th, 2019

SPONSOR: CardioComm Solutions (EKG: TSX-V) – The heartbeat of cardiovascular medicine and telemedicine. Patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centres to access and manage patient information in a secure and reliable environment.

Digital Health Market Value to Reach USD 511 Billion by 2026

  • Demand for digital health is rising on account of the increasing need to improving workflow efficiency across hospitals and other healthcare organizations
  • In addition to this, there is mounting pressure from governments to reduce healthcare costs, while at the same time focus on improving quality of patient care

The global digital health market value is expected to reach around USD 511 billion by 2026.

The global digital health market is expected to rise exponentially in the coming years. The already multi-billion industry is likely to grow at an accelerated pace, as healthcare sector welcomes digitization. Factors such as the advent of mobile health, wireless solutions, and telehealth will foster growth opportunities for the digital health market.

Rising Adoption of mHealth Technologies to Boost Growth

In the coming years, the digital health market is expected to gain pace in response to the rising adoption of mHealth technologies. These are advanced technologies that also help in the self-management of diabetes and other chronic ailments. Taking cue from this, several companies are launching innovative technologies to help in the same. For instance, Glooko was launched specifically to help in the management of diabetes. Similar apps are now increasingly available across smartphones, making it easier for the healthcare professionals and patients alike to keep abreast of the most recent patient information. Development of these technologies is lauded as they are significantly helping in disease diagnosis and monitoring. These are a few of the chief digital health market trends that are likely to enable growth in the coming years. Bolstering this will be the rising penetration of smartphones, smart devices, and better internet connectivity around the world.

Demand for Improving Workflow Efficiency to Boost Uptake in Healthcare Organizations

The demand for digital health is rising on account of the increasing need to improving workflow efficiency across hospitals and other healthcare organizations. In addition to this, there is mounting pressure from governments to reduce healthcare costs, while at the same time focus on improving quality of patient care. Recent advancements in the technology showcased the inclusion of mobile, big data, cloud, and interoperability. Following these developments, a surge in the demand for EHR is observed, subsequently boosting growth prospects for the digital health market. In addition to this, an increasing number of companies are investing in developing innovations in EHR. For instance, Allscripts launched a mobile first and cloud based EHR, dubbed as Avenel, in 2018. The system uses machine learning to bring down time taken for clinical documentation. It works more like an application. Such developments are expected to bode well for the overall market.

Source: https://finance.yahoo.com/news/digital-health-market-value-reach-133000839.html

Tags: , , , , ,
Posted in All Recent Posts, CardioComm Solutions | Comments Off on CardioComm Solutions $EKG.ca – Digital Health #Mhealth Market Value to Reach USD 511 Billion by 2026 $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Loncor $LN.ca – Technical Studies Indicate Possible Bottom and Support for Gold $ABX.ca $TECK.ca $RSG $NGT.to

Posted by AGORACOM at 1:54 PM on Wednesday, November 13th, 2019
This image has an empty alt attribute; its file name is Loncor-Small-Square.png

Sponsor: Loncor is a Canadian gold exploration company focused on two projects in the DRC – the Ngayu and North Kivu projects. Both projects have historic gold production. Exploration at the Ngayu project is currently being undertaken by Loncor’s joint venture partner Barrick Gold. The Ngayu project is 200km southwest of the Kibali gold mine, operated by Barrick, and produced 800,000 ounces of gold in 2018. Barrick manages and funds exploration at the Ngayu project until the completion of a pre-feasibility study on any gold discovery meeting the investment criteria of Barrick. Click Here for More Info

While it is an accepted fact that fundamental events shape the financial markets, many analysts use technical indicators as a way to mathematically quantify market sentiment. One of the simplest and most widely used technical indicators used to determine a current trend for a stock or commodity are moving averages. 

The use of a simple 200-day moving average is used to determine on a long-term basis whether a financial market is currently in a bullish or bearish trend. The use of a 50-day moving average is commonly accepted as determining the short-term trend. In both cases if current pricing is above the moving average than the trend is bullish.

Another widely accepted technical study is based upon the mathematician Leonardo Fibonacci’s golden ratio is Fibonacci retracement theory.

According to Investopedia, “A Fibonacci retracement is a term used in technical analysis that refers to areas of support or resistance. Fibonacci retracement levels use horizontal lines to indicate where possible support and resistance levels are. Each level is associated with a percentage. The percentage is how much of a prior move the price has retraced. The Fibonacci retracement levels are 23.6%, 38.2%, 61.8% and 78.6%. While not officially a Fibonacci ratio, 50% is also used.”

In this article we will use two Fibonacci retracement studies. The first study will be a long-term study; however, this study will utilize much less data then chart number two. The study will begin at the end of 2015 when gold hit a bottom of $1045 per ounce, and concludes at this year’s current high of $1565 per ounce. The second study will be derived from another long-term Fibonacci retracement study which begins in 2008, and concludes in the middle of 2011 when gold reached its record high price against the U.S. dollar.

Of particular interest in the first study are the Fibonacci retracement areas found at the .23%, and .382% retracement levels. Currently gold futures are trading at $1457.40, which is a net decline of $5.50 on the day. This continues the current bearish trend which has been predominant since gold hit its highest value this year in August. When you look at the .38% retracement level on this chart you can see that it precisely defines a level of resistance at approximately $1370.

This was the defined and unbreakable resistance level which began in 2016, the first occurrence of hitting this price point and then trading lower. This resistance was unbreakable throughout 2017 and 2018. In fact, it was not until June of this year that gold was able to breach that price point and trade to its highest value since bottoming out at the end of 2015.

The other level of particular interest is the .23% Fibonacci retracement level which occurs at $1446 per ounce. Currently gold pricing is approximately $11 above that price point. While this study alone will not confirm a potential bottom or support at $1446, it can when combined with other technical indicators, be highly effective in providing price targets for support and resistance.

The second study uses an extremely large data set from 2008 to the middle of 2011 defining the rally which took gold to its all-time record high. Of particular interest is the .38% Fibonacci retracement level which occurs at $1451 per ounce. This defines the lowest price point gold has traded to this month. It also occurs within dollars of the .23% Fibonacci retracement level we looked at on chart 1. When you have two different time sequences which have key Fibonacci retracement levels occur at the same price point, we label this a Fibonacci harmonic.

While one should never use these technical indicators alone, they are excellent tools to define price points to look at when a market is in a corrective stage, which is the current scenario in gold pricing

https://www.kitco.com/commentaries/2019-11-11/Technical-Studies-Indicate-Possible-Bottom-and-Support-for-Gold.html

Tags: , , , , , , , , , ,
Posted in All Recent Posts, Loncor | Comments Off on Loncor $LN.ca – Technical Studies Indicate Possible Bottom and Support for Gold $ABX.ca $TECK.ca $RSG $NGT.to

Gratomic $GRAT.ca – Why The Hype About Graphene? $SRG.ca $NGC.ca $LLG.ca $GPH.ca $NOU.ca

Posted by AGORACOM at 9:22 AM on Wednesday, November 13th, 2019

SPONSOR: Gratomic Inc. (TSX-V: GRAT) Advanced materials company focused on mine to market commercialization of graphite products, most notably high value graphene based components for a range of mass market products. Collaborating with Perpetuus, Gratomic will use Aukam graphite to manufacture graphene products for commercialization on an industrial scale. For More Info Click Here

  • Graphene is the lightest, strongest and most electrically conductive substance on Earth
  • It has many uses in building materials, military equipment and smart technology
  • The Graphene+ 2019 conference at Swinburne will discuss cost-effective and sustainable solutions to industry problems using graphene
Professor Bronwyn Fox will chair a session on the impact of smart factories on jobs and graphene supply chains at the Graphene+ conference held at Swinburne.

Graphene is one of the most innovative materials to be developed and utilised this century.

Researchers at Swinburne have been heavily involved in its development, innovation and commercialisation. Later this month, the university will once again host the annual Graphene+ conference, bringing together industry leaders and academics to discuss the role graphene will play in the future of manufacturing and infrastructure.

What is graphene?

Graphene is both the lightest and strongest material known to man.  It is a single layer of carbon atoms arranged in a honeycomb-like structure and is the most electrically conductive substance on Earth.

It was discovered in 2004 by an unusual technique. Researchers from the University of Manchester in the UK used sticky tape to peel flakes from a lump of graphite, separating the layers until they were just one atom thick.

Graphene has proven highly versatile and has been used for building materials, military equipment, solar cells and smart devices.

Swinburne’s graphene ‘hub’

As part of the Graphene Supply Chain Cooperative Research Centre Projects (CRC-P), Swinburne is working with industry partner Imagine Intelligent Materials to develop graphene to meet strict quality assurances and to be used in large-scale manufacturing. It is also working to establish industry partnerships.

The material is also a key focus of the Next Generation Materials program, led by Professor Baohua Jia at Swinburne’s Manufacturing Future Research Institute (MFRI).

Director of the Manufacturing Future Research Institute, Professor Bronwyn Fox, says Swinburne researchers are working to establish standard knowledge and procedures for investors and suppliers of graphene.

“In the supply chain certification lab, we are developing the research to understand the relationship between the structure and performance of graphene so that industry can have security of supply, ensure successful applications and strengthen future investments in the technologies that utilise this material.”

Swinburne researchers have analysed the complete graphene supply chain – from production to industry practice. They have investigated graphene’s properties and tested its ability to combine with other materials in engineering developments, as well its potential to be used as a thin, protective coating. 

Graphene+ 2019

The use of graphene in the development of smart cities will be high on the agenda at the 2019 Graphene+ conference.

Other topics to be discussed include:

  • Upgrading sensing equipment for the Internet of Things (IoT)
  • Creating stronger, lightweight architectural structures using the latest in robotics technology
  • Commercialisation of one-step water purification systems to make drinking water universally available
  • Enhancing the harnessing and conserving of energy
  • Jobs of the future – how will graphene change the industry?

Researchers will share knowledge and discuss the potential of advanced, sustainable and cost-effective technologies, contributing to the establishment of cities that thrive on smart devices and infrastructure.

Professor Fox will also chair a session on the impact of smart factories on jobs and graphene supply chains.

“We are fortunate to have some world-leading local and international speakers. The discussions will give us a glimpse of what the future might look like with graphene at the forefront of technology.”

Source: http://www.swinburne.edu.au/news/latest-news/2019/11/why-the-hype-about-graphene.php

Tags: , , , , , , , , , ,
Posted in All Recent Posts, Gratomic | Comments Off on Gratomic $GRAT.ca – Why The Hype About Graphene? $SRG.ca $NGC.ca $LLG.ca $GPH.ca $NOU.ca

« Older Entries
Newer Entries »